01
Antibody conjugation
A simplified, stable labelling chemistry anchors the antibody to the particle surface without collapsing the particle or burying its binding site.
Antibody-conjugated LNP-RNA medicines
Programming the cell the disease depends on.
Promax Bioscience builds antibody-conjugated lipid nanoparticles that carry RNA instructions to pathological cells in situ — turning systemic dosing into precise, programmable therapy.
- Linyi, Shandong
- Founded 2023
- Ab-LNP_mRNA · Ab-LNP_CRISPR
The company
A delivery company at heart.
Promax Bioscience is a biopharmaceutical company developing antibody-conjugated LNP-RNA medicines. Our work addresses the central limitation of genetic medicine: an RNA instruction is easy to write, and very hard to place.
By anchoring antibodies to the surface of lipid nanoparticles, we redirect RNA payloads away from default clearance organs and toward the cells that actually drive disease. The payload then does what RNA does best — it reprograms the cell in place.
2
Integrated payload modalities
mRNA and CRISPR sgRNA
4
Therapeutic areas in focus
Oncology · Cardiovascular · Inflammation · Neuro
6
Layers in our AI R&D system
From instrument to governance
1
Backbone across the pipeline
One Ab-LNP platform
Our platform
One backbone. Two payloads. Any cell we can target.
The platform is deliberately modular: the antibody decides the destination, the payload decides the effect, and the process stays the same.
02
Protein corona control
A tuned universal protein corona suppresses unproductive clearance and keeps the targeting antibody available to its receptor in circulation.
03
In-situ cell engineering
mRNA or sgRNA payloads rewrite the behaviour of pathological cells where they live — tumour cells, foam cells, fibroblasts, modulated smooth muscle cells.
04
AI-driven development
A six-layer system connects instruments, data, decisions and quality into one traceable loop, so every experiment compounds.
Pipeline
AI drug development and clinical optimization, grounded in a paradigm shift in the life sciences.
Three lead programs across cardiovascular, oncology and aging. Each runs on the same Ab-LNP backbone, configured to target a different cell population.
ProgramTherapeutic areaLead indicationStage
HYLG-B1002
Program
Cardiovascular & metabolic
Atherosclerosis
Preclinical
HYLG-B1004
Program
Oncology
Colorectal cancer
Preclinical
HYLG-B1010
Program
Anti-aging
Aging prevention
Lead optimization
Discovery programs
Program
Anti-infective, neuro & regenerative medicine
Undisclosed
Discovery
Program stages are internal development estimates and are updated as programs advance.
Why it matters
Extrahepatic delivery is the bottleneck of RNA medicine.
Lipid nanoparticles naturally accumulate in the liver and spleen. The antibody is what sets the target. Our conjugation chemistry, corona control and modular process design exist to make that redirection reproducible — and manufacturable.
01
Precision over dose
Targeting replaces escalation. Lower systemic exposure, higher local instruction, and a safety margin that does not depend on volume.
02
Modular by design
One backbone, many antibodies. Assets share processes, analytics and production lines, so a new target is a configuration — not a new factory.
03
Data-native development
Every experiment is captured in a structured AI layer. Decisions accumulate as institutional memory instead of resetting with each program.
Therapeutic focus
Where cell-level precision changes the outcome.
Oncology & inflammation
In-situ programming of tumour and immune cells to produce therapeutic proteins inside the lesion.
Cardiovascular & metabolic
Targeting the modulated cell populations that drive plaque formation and metabolic dysfunction.
Anti-infective & immunology
Local immune instruction at mucosal surfaces, including prevention-and-treatment formats.
Neuro & regenerative medicine
Delivery strategies for tissue repair where cell replacement is not accessible.
Newsroom
Latest from Promax
Partner with us
The next program starts with a conversation.
We work with academic groups, biotech partners and manufacturers on antibody selection, payload design and process transfer.